抑制素。

IF 11.2 1区 医学 Q1 PHARMACOLOGY & PHARMACY Annual review of pharmacology and toxicology Pub Date : 2020-02-07 DOI:10.32388/5bw2ar
C. Li, K. Ramasharma
{"title":"抑制素。","authors":"C. Li, K. Ramasharma","doi":"10.32388/5bw2ar","DOIUrl":null,"url":null,"abstract":"Inhibin is a glycoprotein which specifically inhibits FSH secretion. In follicular fluid, several forms of inhibin have been identified with mol. wts between 120 and 32 kd. The smallest active form is a glycosylated 32-kd protein with an 18-kd A chain and a 13-kd B chain. The secretion of inhibin by granulosa cells of the follicle is stimulated by FSH and testosterone, but not LH, and treatment of women with clomiphene and HMG/FSH results in an increase in the plasma concentration of inhibin. However, during the follicular phase of the normal menstrual cycle, FSH is inhibited mainly by oestradiol and inhibin levels remain constant or decline in parallel with those of FSH. It is probable that inhibin and oestradiol act together to cause the suppression of FSH. During the luteal phase, the human corpus luteum under the influence of LH secretes inhibin as well as oestradiol and progesterone. This combined negative feedback signal from the corpus luteum accounts for the suppression of FSH release and thus the failure of follicular growth during the luteal phase.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"58 10","pages":"1-21"},"PeriodicalIF":11.2000,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Inhibin.\",\"authors\":\"C. Li, K. Ramasharma\",\"doi\":\"10.32388/5bw2ar\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Inhibin is a glycoprotein which specifically inhibits FSH secretion. In follicular fluid, several forms of inhibin have been identified with mol. wts between 120 and 32 kd. The smallest active form is a glycosylated 32-kd protein with an 18-kd A chain and a 13-kd B chain. The secretion of inhibin by granulosa cells of the follicle is stimulated by FSH and testosterone, but not LH, and treatment of women with clomiphene and HMG/FSH results in an increase in the plasma concentration of inhibin. However, during the follicular phase of the normal menstrual cycle, FSH is inhibited mainly by oestradiol and inhibin levels remain constant or decline in parallel with those of FSH. It is probable that inhibin and oestradiol act together to cause the suppression of FSH. During the luteal phase, the human corpus luteum under the influence of LH secretes inhibin as well as oestradiol and progesterone. This combined negative feedback signal from the corpus luteum accounts for the suppression of FSH release and thus the failure of follicular growth during the luteal phase.\",\"PeriodicalId\":8057,\"journal\":{\"name\":\"Annual review of pharmacology and toxicology\",\"volume\":\"58 10\",\"pages\":\"1-21\"},\"PeriodicalIF\":11.2000,\"publicationDate\":\"2020-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annual review of pharmacology and toxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.32388/5bw2ar\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of pharmacology and toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32388/5bw2ar","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

抑制素是一种专门抑制FSH分泌的糖蛋白。在卵泡液中,几种抑制素的分子量在120 - 32kd之间。最小的活性形式是32 kd的糖基化蛋白,具有18 kd的a链和13 kd的B链。卵泡颗粒细胞分泌抑制素受到卵泡刺激素和睾酮的刺激,而不是黄体生成素的刺激,用克罗米芬和HMG/FSH治疗的妇女导致血浆中抑制素浓度的增加。然而,在正常月经周期的卵泡期,卵泡刺激素主要受雌二醇抑制,抑制素水平与卵泡刺激素水平保持不变或平行下降。可能是抑制素和雌二醇共同作用导致FSH的抑制。在黄体期,人黄体在黄体生成素的影响下,分泌抑制素以及雌二醇和黄体酮。这种来自黄体的联合负反馈信号解释了FSH释放的抑制,从而导致黄体期卵泡生长的失败。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Inhibin.
Inhibin is a glycoprotein which specifically inhibits FSH secretion. In follicular fluid, several forms of inhibin have been identified with mol. wts between 120 and 32 kd. The smallest active form is a glycosylated 32-kd protein with an 18-kd A chain and a 13-kd B chain. The secretion of inhibin by granulosa cells of the follicle is stimulated by FSH and testosterone, but not LH, and treatment of women with clomiphene and HMG/FSH results in an increase in the plasma concentration of inhibin. However, during the follicular phase of the normal menstrual cycle, FSH is inhibited mainly by oestradiol and inhibin levels remain constant or decline in parallel with those of FSH. It is probable that inhibin and oestradiol act together to cause the suppression of FSH. During the luteal phase, the human corpus luteum under the influence of LH secretes inhibin as well as oestradiol and progesterone. This combined negative feedback signal from the corpus luteum accounts for the suppression of FSH release and thus the failure of follicular growth during the luteal phase.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
27.80
自引率
0.00%
发文量
53
期刊介绍: Since 1961, the Annual Review of Pharmacology and Toxicology has been a comprehensive resource covering significant developments in pharmacology and toxicology. The journal encompasses various aspects, including receptors, transporters, enzymes, chemical agents, drug development science, and systems like the immune, nervous, gastrointestinal, cardiovascular, endocrine, and pulmonary systems. Special topics are also featured in this annual review.
期刊最新文献
How Biologics Have Changed the Drug Discovery Landscape. Inhibitors of Intracellular RyR2 Calcium Release Channels as Therapeutic Agents in Arrhythmogenic Heart Diseases. Targeting Neuroplasticity in Substance Use Disorders: Implications for Therapeutics. Evolving Approaches for Pharmacological Therapy of Obesity. Genetically Enriched Clinical Trials for Precision Development of Noncancer Therapeutics: A Scoping Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1